Abstract
The aim of this study is to compare the efficacy and safety of PRP, Corticosteroids and placebo injections for the treatment of chronic lateral epicondylitis. .The objectives were to study pain and function using various tools like VAS (Visual Analouge Score), Function and Disability score for both PRP and Corticosteroid. Keywords: Platelate rich plasma, Corticosteriods, Chronic lateral epicondylitis
Highlights
Lateral Epicondylitis is the most commonly diagnosed condition of the Elbow and affects approx. 1% to 3% of the population
Collagen is an attractive alternative to bovine thrombin as it is naturally involved in the intrinsic clotting cascade. We found that both Platelete Rich Plasma (PRP) and Corticosteroids significantly improve the VAS score vs Placebo treatment in the short term and long term
We conducted a prospective comparative study of 90 patients of chronic lateral epicondylitis treated with either PRP, corticosteroid or placebo injection
Summary
Lateral Epicondylitis is the most commonly diagnosed condition of the Elbow and affects approx. 1% to 3% of the population. Lateral Epicondylitis is the most commonly diagnosed condition of the Elbow and affects approx. This condition mostly occurs in patients whose activities require repetitive wrist movements and strong gripping. It is thought the leisons occurs in the common origins of wrist and finger extensors on the Lateral Epicondyle. ECRB origin is the most commonly sited location of Lateral Epicondylitis pathology. Kraushaar & Nirschl described 4 stages of tendonosis. Stage 1 is described as Peritendonous Inflammation (Tendonitis). Stage 2,3,4 refer to the presence of angiofibroblastic degeneration
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Orthopaedics Traumatology & Surgical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
